| Literature DB >> 26355010 |
Diane Farrar1, Lesley Fairley2, Gillian Santorelli3, Derek Tuffnell4, Trevor A Sheldon5, John Wright2, Lydia van Overveld6, Debbie A Lawlor7.
Abstract
BACKGROUND: Diagnosis of gestational diabetes predicts risk of infants who are large for gestational age (LGA) and with high adiposity, which in turn aims to predict a future risk of obesity in the offspring. South Asian women have higher risk of gestational diabetes, lower risk of LGA, and on average give birth to infants with greater adiposity than do white European women. Whether the same diagnostic criteria for gestational diabetes should apply to both groups of women is unclear. We aimed to assess the association between maternal glucose and adverse perinatal outcomes to ascertain whether thresholds used to diagnose gestational diabetes should differ between south Asian and white British women. We also aimed to assess whether ethnic origin affected prevalence of gestational diabetes irrespective of criteria used.Entities:
Mesh:
Year: 2015 PMID: 26355010 PMCID: PMC4673084 DOI: 10.1016/S2213-8587(15)00255-7
Source DB: PubMed Journal: Lancet Diabetes Endocrinol ISSN: 2213-8587 Impact factor: 32.069
Different criteria used for diagnosis of gestational diabetes
| Fasting | 1 h post-load | 2 h post-load | |||
|---|---|---|---|---|---|
| HAPO exclusion | 5·8 | .. | 11·1 | 2002 | Some US cities |
| WHO (previous) | 7·0 | .. | 7·8 | 1999–2013 | Widespread worldwide |
| WHO (previous, modified) | 6·1 | .. | 7·8 | 1999 to present | UK |
| UK NICE | 5·6 | .. | 7·8 | 2015 | UK |
| IADPSG and WHO (present) | 5·1 | 10·8 | 8·5 | 2010/13 to present | Widespread worldwide |
HAPO=Hyperglycaemia and Adverse Pregnancy Outcomes study. NICE=National Institute for health and Care Excellence. IADPSG=International Association of Diabetes and Pregnancy Study Groups.
All values are for a glucose tolerance test undertaken at about 26–28 weeks of gestation.
Figure 1Study sample
The criteria used in the hospital in which study participants were recruited to diagnose gestational diabetes (and hence exclude them from the analyses presented here) were either fasting glucose ≥6·1 mmol/L or 2 h post-load glucose ≥7·8 mmol/L.
Confounder-adjusted association of gestational fasting and 2 h post-load glucose with primary outcomes
| Birthweight >90th percentile | |||||
| 1 (Reference) | 1·00 | 1·00 | 1·00 | 0·39 | |
| 2 | 1·18 (0·90–1·54) | 1·15 (0·83–1·59) | 1·07 (0·59–1·94) | .. | |
| 3 | 1·35 (1·04–1·74) | 1·38 (1·01–1·90) | 1·10 (0·65–1·88) | .. | |
| 4 | 1·42 (1·02–1·97) | 1·57 (1·04–2·37) | 1·05 (0·56–1·98) | .. | |
| 5 | 1·90 (1·35–2·67) | 1·59 (0·97–2·62) | 2·12 (1·20–3·76) | .. | |
| 6 | 3·10 (2·00–4·79) | 2·21 (1·07–4·54) | 3·35 (1·72–6·51) | .. | |
| 7 | 2·60 (1·35–5·04) | 2·09 (0·80–5·48) | 3·25 (1·29–8·21) | .. | |
| Per 1 SD | 1·31 (1·20–1·43) | 1·22 (1·08–1·38) | 1·43 (1·23–1·67) | .. | |
| Sum of skinfolds >90th percentile | |||||
| 1 (reference) | 1·00 | 1·00 | 1·00 | 0·98 | |
| 2 | 1·11 (0·88–1·40) | 1·04 (0·74–1·46) | 1·29 (0·92–1·82) | .. | |
| 3 | 1·40 (1·14–1·72) | 1·35 (0·96–1·88) | 1·56 (1·15–2·13) | .. | |
| 4 | 1·61 (1·24–2·09) | 1·69 (1·09–2·62) | 1·70 (1·18–2·45) | .. | |
| 5 | 2·02 (1·54–2·64) | 2·05 (1·26–3·36) | 2·15 (1·49–3·10) | .. | |
| 6 | 3·23 (2·29–4·56) | 3·20 (1·52–6·74) | 3·18 (2·01–5·02) | .. | |
| 7 | 2·73 (1·53–4·87) | 2·71 (0·97–7·58) | 3·06 (1·44–6·51) | .. | |
| Per 1 SD | 1·35 (1·25–1·45) | 1·35 (1·18–1·54) | 1·35 (1·23–1·49) | .. | |
| Caesarean delivery | |||||
| 1 (reference) | 1·00 | 1·00 | 1·00 | 0·47 | |
| 2 | 0·98 (0·84–1·13) | 1·03 (0·83–1·27) | 0·99 (0·79–1·24) | .. | |
| 3 | 1·11 (0·96–1·28) | 1·06 (0·86–1·32) | 1·20 (0·97–1·49) | .. | |
| 4 | 1·17 (0·97–1·41) | 1·11 (0·81–1·51) | 1·33 (1·03–1·73) | .. | |
| 5 | 1·20 (0·98–1·48) | 1·18 (0·83–1·69) | 1·18 (0·88–1·56) | .. | |
| 6 | 1·14 (0·84–1·55) | 1·42 (0·83–2·45) | 1·02 (0·67–1·56) | .. | |
| 7 | 2·14 (1·34–3·41) | 1·25 (0·57–2·77) | 2.88 (1·58–5·25) | .. | |
| Per 1 SD | 1·09 (1·03–1·15) | 1·06 (0·97–1·16) | 1·11 (1·02–1·20) | .. | |
| Birthweight >90th percentile | |||||
| 1 (reference) | 1·00 | 1·00 | 1·00 | 0·60 | |
| 2 | 0·95 (0·74–1·23) | 1·00 (0·73–1·37) | 0·96 (0·56–1·66) | .. | |
| 3 | 1·08 (0·83–1·39) | 0·98 (0·71–1·36) | 1·04 (0·61–1·76) | .. | |
| 4 | 1·29 (0·92–1·80) | 1·20 (0·78–1·84) | 1·39 (0·72–2·66) | .. | |
| 5 | 1·58 (1·14–2·19) | 1·18 (0·76–1·82) | 2·12 (1·15–3·93) | .. | |
| 6 | 1·71 (1·04–2·81) | 1·74 (0·90–3·36) | 1·66 (0·69–3·98) | .. | |
| 7 | 1·29 (0·65–2·60) | 1·27 (0·50–3·26) | 1·64 (0·54–5·05) | .. | |
| Per 1 SD | 1·17 (1·07–1·29) | 1·10 (0·98–1·24) | 1·28 (1·06–1·55) | .. | |
| Sum of skinfolds >90th percentile | |||||
| 1 (reference) | 1·00 | 1·00 | 1·00 | 0·23 | |
| 2 | 1·02 (0·81–1·29) | 1·24 (0·88–1·73) | 0·96 (0·68–1·35) | .. | |
| 3 | 1·32 (1·05–1·65) | 1·13 (0·78–1·63) | 1·51 (1·10–2·07) | .. | |
| 4 | 1·84 (1·40–2·41) | 1·76 (1·12–2·76) | 1·94 (1·33–2·83) | .. | |
| 5 | 1·94 (1·47–2·55) | 1·79 (1·13–2·82) | 2·22 (1·52–3·25) | .. | |
| 6 | 2·29 (1·54–3·39) | 2·63 (1·35–5·14) | 2·13 (1·25–3·64) | .. | |
| 7 | 2·53 (1·53–4·17) | 1·80 (0·68–4·77) | 3·13 (1·71–5·74) | .. | |
| Per 1 SD | 1·31 (1·21–1·42) | 1·26 (1·11–1·42) | 1·38 (1·23–1·54) | .. | |
| Caesarean delivery | |||||
| 1 (reference) | 1·00 | 1·00 | 1·00 | 0·54 | |
| 2 | 0·95 (0·82–1·10) | 0·89 (0·72–1·11) | 1·06 (0·84–1·32) | .. | |
| 3 | 1·07 (0·92–1·24) | 1·09 (0·87–1·37) | 1·01 (0·80–1·27) | .. | |
| 4 | 1·11 (0·91–1·36) | 0·96 (0·70–1·32) | 1·19 (0·89–1·60) | .. | |
| 5 | 1·00 (0·81–1·23) | 1·03 (0·76–1·42) | 0·97 (0·71–1·33) | .. | |
| 6 | 1·31 (0·96–1·79) | 1·12 (0·68–1·85) | 1·35 (0·88–2·07) | .. | |
| 7 | 1·15 (0·76–1·74) | 0·86 (0·43–1·72) | 1·29 (0·72–2·29) | .. | |
| Per 1 SD | 1·05 (0·99–1·11) | 1·02 (0·94–1·10) | 1·05 (0·96–1·14) | .. | |
Testing the null hypothesis that the associations of glucose categories with outcome do not differ between white British and south Asian women.
Glucose categories are defined as follows: fasting plasma glucose level category 1: <4·3 mmol/L; category 2: 4·3–4·4 mmol/L; category 3: 4·5–4·7 mmol/L; category 4: 4·8–4·9 mmol/L; category 5: 5·0–5·2 mmol/L; category 6: 5·3–5·6 mmol/L; category 7: 5·7–6·0 mmol/L. Post-load plasma glucose level category 1: <4·7 mmol/L; category 2: 4·7–5·4 mmol/L; category 3: 5·5–6·2 mmol/L; category 4: 6·3–6·6 mmol/L; category 5: 6·7–7·2 mmol/L; category 6: 7·3–7·5 mmol/L; category 7: 7·6–7·7 mmol/L.
Figure 2Frequency of primary outcomes across glucose categories by ethnic origin (white British [N=3888] and south Asian [N=4821])
Glucose categories are defined as follows: fasting plasma glucose level category 1: <4·3 mmol/L; category 2: 4·3–4·4 mmol/L; category 3: 4·5–4·7 mmol/L; category 4: 4·8–4·9 mmol/L; category 5: 5·0–5·2 mmol/L; category 6: 5·3–5·6 mmol/L; category 7: 5·7–6·0 mmol/L. Post-load plasma glucose level category 1: <4·7 mmol/L; category 2: 4·7–5·4 mmol/L; category 3: 5·5–6·2 mmol/L; category 4: 6·3–6·6 mmol/L; category 5: 6·7–7·2 mmol/L; category 6: 7·3–7·5 mmol/L; category 7: 7·6–7·7 mmol/L.
Thresholds of fasting and post-load glucose concentrations that would identify an odds ratio of roughly 1·75 for birthweight >90th percentile and sum of skinfolds >90th percentile
| Fasting glucose threshold (mmol/L) | 2 h post-load glucose threshold (mmol/L) | Fasting glucose threshold (mmol/L) | 2 h post-load glucose threshold (mmol/L) | Fasting glucose threshold (mmol/L) | 2 h post-load glucose threshold (mmol/L) | |
|---|---|---|---|---|---|---|
| Birthweight >90th percentile | 5·3 | NP | 5·6 | NP | 5·1 | NP |
| Sum skinfolds >90th percentile | 5·2 | 7·5 | 5·2 | NP | 5·2 | 7·2 |
| Average glucose concentration for both birthweight and sum of skinfolds >90th percentile | 5·3 | 7·5 | 5·4 | NP | 5·2 | 7·2 |
NP=not possible to work out a threshold because within our study none of the women reached a threshold that gave an odds ratio of 1·75 or greater (the International Association of Diabetes and Pregnancy Study Groups consensus minimal odds ratio deemed to be of clinical importance).
Prevalence of gestational diabetes in south Asian and white British women using different criteria
| Fasting glucose (mmol/L) | 1 h post-load glucose (mmol/L) | 2 h post-load glucose (mmol/L) | White British | South Asian | |
|---|---|---|---|---|---|
| Exclusion in HAPO | 5·8 | .. | 11·1 | 1% (0·9–1·5) | 4% (3·6–4·7) |
| WHO (previous) | 7·0 | .. | 7·8 | 5% (4·1–5·4) | 10% (9·6–11·2) |
| WHO (previous, modified) | 6·1 | .. | 7·8 | 5% (4·3–5·6) | 11% (10·0–11·7) |
| UK NICE | 5·6 | .. | 7·8 | 6% (5·2–6·6) | 13% (11·7–13·4) |
| IADPSG/WHO (current) | 5·1 | 10·8 | 8·5 | 8% (6·8–8·5) | 17% (16·3–18·3) |
| Same criteria for all women | 5·3 | .. | 7·5 | 9% (7·9–9·6) | 17% (16·4–18·4) |
| For white British | 5·4 | .. | 7·5 | 8% (7·5–9·2) | .. |
| For south Asian | 5·2 | .. | 7·2 | .. | 24% (23·1–25·3) |
HAPO=Hyperglycaemia and Adverse Pregnancy Outcomes study. NICE=National Institute for health and Care Excellence. IADPSG=International Association of Diabetes and Pregnancy Study Groups.
Used in the HAPO study to exclude women with gestational diabetes.
Used by WHO up to 2013.
Criteria used for all pregnant women in Bradford (and in other populations) at the time that women were recruited for the Born in Bradford study and used here to exclude those with gestational diabetes.
Criteria in current UK guidelines.
Criteria were developed using HAPO data and were adopted by WHO in 2013.2, 3
Criteria developed in this study.